Augustin Delago, MD
Cardiovascular Disease · Albany, NYNPI 1114911633
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 62.7% of it on its own, with 36 other manufacturers making up the rest. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,969 payments — averaging $937.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$1.2M
- Boston Scientific$574K
- Baylis Medical Company Inc$69K
- Abbott$32K
- Siemens Medical Solutions USA, Inc.$4K
- Novartis$1K
- plus $7K from 31 others
Across 20 payments — averaging $5303.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$106K
- Abbott$21
What the payments were for
- Consulting fees$1,058,03157%
- Speaking & faculty fees$661,46336%
- Travel & lodging$84,0005%
- Food & beverage$41,3332%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 784 | $1,157,022 |
| Boston Scientific | 537 | $574,171 |
| Baylis Medical Company Inc | 19 | $69,313 |
| Abbott | 141 | $32,227 |
| Siemens Medical Solutions USA, Inc. | 2 | $4,175 |
| Novartis | 101 | $1,197 |
| E.r. Squibb & Sons, L.L.C. | 63 | $900 |
| Amgen | 48 | $812 |
| Pfizer | 60 | $755 |
| Chiesi USA, Inc. | 48 | $572 |
| Johnson & Johnson | 24 | $425 |
| Abiomed | 11 | $396 |
| AstraZeneca | 21 | $348 |
| AOP Health US, LLC | 1 | $326 |
| Angiodynamics, Inc. | 2 | $302 |
| Medtronic(2 entities) | 8 | $287 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $250 |
| Merck | 13 | $204 |
| Esperion Therapeutics, Inc. | 10 | $202 |
| Shockwave Medical, Inc | 1 | $197 |
| Boehringer Ingelheim | 10 | $151 |
| Sanofi-aventis U.S. LLC | 7 | $130 |
| Gilead | 12 | $122 |
| Lexicon Pharmaceuticals, Inc. | 3 | $57 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $57 |
| Bayer | 3 | $54 |
| Alnylam Pharmaceuticals Inc. | 3 | $50 |
| Bard Peripheral Vascular, Inc. | 1 | $46 |
| Bridgebio Pharma, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $23 |
| Opsens Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Terumo Medical Corporation | 1 | $13 |
| Cvrx, Inc. | 1 | $12 |
| Procyrion, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,033,961
- VersaCross Access Solution$338,625
- Watchman$61,789
- Sentinel$42,813
- GENERAL - THERAPIES$37,770
- GENERAL - STRUCTURAL HEART$30,641
- VersaCross Large Access Solution$26,250
- Mitra Clip system$18,191
- VersaCross Steerable Access Solution$17,500
- NRG needle$16,763
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$13,238
- GENERAL VASCULAR ACCESS$11,354
- WATCHMAN Access System$10,279
- VersaCross Transseptal Sheath$8,750
- LOTUS EDGE$8,666
- WATCHMAN FLX$7,905
- MitraClip$7,114
- SAPIEN 3 Ultra RESILIA$4,234
- VersaCross$3,500
- EVOQUE$2,720
How this compares
$1,844,953 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $24,051 |
| Amoxicillin | 84 | $383 |
| Metoprolol Succinate | 19 | $267 |
| ClopidogrelClopidogrel Bisulfate | 30 | $247 |
| Losartan Potassium | 11 | $124 |
| Atorvastatin Calcium | 14 | $110 |
| Lisinopril | 12 | $107 |
| Furosemide | 20 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $755 | $24,05126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Albany
- Rizwan AlimohammadAlbany$349K
- Edward PhilbinAlbany$226K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.